Data completeness
2/8 — Basic
ISONIAZID by Eli Lilly and Company is clinical pharmacology within 1 to 2 hours after oral administration, isoniazid produces peak blood levels which decline to 50 percent or less within 6 hours.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Isoniazid is a small-molecule bactericidal antibiotic that inhibits mycolic acid synthesis in the bacterial cell wall, making it essential for tuberculosis treatment. It is indicated for active tuberculosis, latent tuberculosis infection, tuberculous meningitis, and has secondary indications in HIV co-infection and severe acute malnutrition contexts. The drug works against both intracellular and extracellular Mycobacterium tuberculosis organisms at therapeutic levels.
Pre-Launch
Pre-launch stage with Eli Lilly sponsorship suggests a rebuilding or repositioning effort in TB therapy, likely requiring modest commercial team expansion during launch phase.
Mechanism of Action
CLINICAL PHARMACOLOGY Within 1 to 2 hours after oral administration, isoniazid produces peak blood levels which decline to 50 percent or less within 6 hours. It diffuses readily into all body fluids (cerebrospinal, pleural, and ascitic fluids), tissues, organs, and excreta (saliva, sputum, and…
Indications
Worked on ISONIAZID at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.